Dr. Clay Siegall has discovered the company Seattle Genetics in the year 1998. Seattle Genetics under his leadership has made multiple pipelines of cancer therapies. Dr. Siegall has got over $675 million through private and public financings. Dr. Siegall used to be with Bristol-Myers Institute also. He is the has over seventy publications and has fifteen patents.
Dr. Siegall has got a Ph.D. in Genetics from George Washington University and a B.S in Zoology from Maryland University. He has built Seattle Genetics by scientific modernization and intense research. He is passionate to assist the patients.
He has given guidance to the company for its leadership in making antibody-drug combinations. He has got a different channel of antibody drug variations for cancer treatment. He has expertise in the creation of targeted therapy drugs for various kinds of diseases.
Dr. Siegall has got great plans for the future of the company. He has got a big list of medicines for the creation of the pipelines, and there are many signs for the firm’s current drug collection. He is in a high position in the drug development arena.
Seattle Genetics is known to have got into many crucial licenses for its technology on ADC. There are over twenty ADCs in the clinical development. These make use of the Seattle Genetic engineering.
Dr. Siegall has over $1.2 billion via public and private finances. Dr. Siegall has got many awards, and those include the Maryland University award in the year 2013. He is also the author of over seventy publications and has got fifteen patents.
He is known to be a Ph.D. in Genetics from George Washington University. He has done B.S in Zoology from Maryland University. The main aim of Seattle Genetics is to assist the patients. Mr. Siegall’s primary objective is the treatment of cancer patients and does much better than that.
One vital aspect of Mr. Siegall’s strategy is to work in close association with other leaders in the industry. Mr. Clay Siegall has been on the Board of Directors of a private biotechnology company. He has laid down the foundation of various drug development practices and extensive research.